Document is current

Article History

Received: 13 January 2022

Accepted: 17 March 2022

First Online: 26 March 2022

Declarations

:

: Patients involved in the study have been enrolled in the CAVE-Lung trial (EUDRACT 2017–004195-58) and have signed the specific informed consent for participation, that was approved by local Ethic Committee.

: Patients involved in the study have been enrolled in the CAVE-Lung trial (EUDRACT 2017–004195-58) and have signed the specific informed consent for publication, that was approved by local Ethic Committee.

: CMDC, advisory board MSD; MF, family relationship Merck, advisory board for MSD and Merck Serono; CMG, Advisory Board - Jazz Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Speaker’s Bureau - AstraZeneca, BeiGene; RDL, Advisory Board Astellas; EM, advisor and speaker for Astra Zeneca, Amgen, Bayer, Merck-Serono, Roche, Sanofi, Servier, Pierre Fabre; TT, advisor and speaker for Roche, Merck-Serono, Sanofi, Servier, Novartis, Bayer; L.A.B., advisory committees for AstraZeneca, AbbVie, Merck Sharp & Dohme Corp., Genentech Inc., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co, and BeiGene and has research support from AstraZeneca; FM: advisory boards: MSD, Lilly; institutional research grants: AstraZeneca; FC, advisor and speaker for Roche, Amgen, Merck-Serono, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene, Lilly, institutional Research Grants form Bayer, Roche, Merck-Serono, Amgen, AstraZeneca, Takeda. Other authors have no conflicts of interest to declare.